Company · Private
BlueRock Therapeutics
Engineered cell therapies derived from induced pluripotent stem cells, with a lead Parkinson's programme.
EvidenceModerate
Listing
Private
Ticker
—
Headquarters
Cambridge, US
Founded
2016
Technology
iPSC-derived cell therapy
Category
Market cap
Private
Longevity thesis
Manufactured, off-the-shelf cells make regenerative medicine scalable.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| bemdaneprocel | Phase 3 | Parkinson's disease |
Recent developments
- 9 Jul 2026Advanced its dopaminergic cell therapy into a registrational study.
Scientific evidence
EvidenceModerate
Human data with multi-year follow-up in a defined indication.
LONGEFI analysis
A credible signal that iPSC manufacturing has matured; relevant to any future rejuvenation therapy that requires cell products.
Analysis is research commentary. It is not investment advice or a recommendation.